Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 4, 2020

Primary Completion Date

June 3, 2021

Study Completion Date

June 3, 2021

Conditions
Neuroendocrine TumorsPheochromocytomaParaganglioma
Interventions
DRUG

177Lu-DOTA-tyr3-OCTREOTATE

This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.

PROCEDURE

Peptide Receptor Radiotherapy (PRRT)

PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors
All Listed Sponsors
collaborator

Advanced Accelerator Applications

INDUSTRY

lead

Sue O'Dorisio

OTHER